The second study limitation is the unavailable information on the number of BM, Karnofsky performance status, comorbidities, extracranial disease, LM, aggregate brain tumor volume or BRAF status, some of which have been confirmed to be potential important prognostic indicators.23, 24, 25 Third, although our nomogram was validated using two methods and presented strong agreement between the nomogram‐predicted survival and the actual survival, external validation is needed in the future to validate the recommended nomogram. This evidence concerns the gene BRAF and brain neoplasm.